HORSHAM, Pa., Oct. 01, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”), a medical
technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products
for the treatment of dermatologic conditions, today announced the completion of a multi-center clinical study investigating the
efficiency and efficacy of its FDA cleared Multi-Micro Dose™ (“MMD”) diagnostic tip accessory for the proprietary XTRAC® 308nm
excimer laser.
Three separate clinics utilized the patent-pending MMD tip, in conjunction with the XTRAC laser, to filter the narrow band UVB
light at delivery in order to calculate and customize the maximum non-blistering dose for each of the participating patients in the
study.
The MMD tip simultaneously applies multiple level doses of energy to a specific area of a patient’s psoriatic plaque, thereby
identifying the maximum sub-blistering energy dose for a particular treatment zone. Utilizing the results from these test patches,
the physician can design the optimal therapeutic dose treatment for each patient. This proprietary process was trademarked by
STRATA as the Optimal Therapeutic Dose (OTD) and is intended to provide faster patient outcomes and greater patient satisfaction.
The clinical study was designed to measure increased efficacy and determine the minimum number of treatment sessions necessary to
achieve desired clinical endpoints.
Following the OTD process, the physician determines the maximum non-blistering dose for the patient’s psoriatic plaque. Data
have shown that higher doses of the XTRAC treatment achieved PASI-75 clearance in as little as two to four weekly treatments, as
compared to an average of 6.2 treatments, shown in previously published studies at lower doses.
The statistical analysis of the clinical study results, based on the XTRAC treatment protocol which utilized the Optimal
Therapeutic Dose (OTD), revealed the following findings:
- 92% of the included participants responded to treatment by achieving a reduction in mPASI score of 75% or more
- As compared to the current average of 16-20 treatments conducted with NB-UVB 308nm devices, the treatment produced
statistically significant mPASI improvement by the second treatment. It took an average of
four sessions for patients to reduce mPASI by 50% or more relative to baseline
- Patients were followed post treatment and have maintained reduction in mPASI score of 50% or more for 60 days
- Further, statistical survival models predict mPASI scores to stay below 50% of baseline for 78 days
The company anticipates the full clinical study report to be submitted for publication.
Dr. Ben Lockshin, former Chair of the Research Committee and on the Board of Directors for the National Psoriasis Foundation
(NPF) and a principal investigator on this study, stated, “I am pleased to see how quickly my patients can achieve meaningful
improvement in just a few treatments. I believe this will greatly increase patient satisfaction.”
Dr. Lockshin, has engaged with the company to become the first commercial site providing OTD XTRAC treatments using the MMD tip,
and further commented, “I believe integrating the OTD approach will allow me to provide the safe and effective treatment that
reduces the time commitment and cost for my patients while achieving the clinical results we have come to expect with XTRAC.”
Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, noted, “Introducing the Optimal Therapeutic Dose™ treatment protocol and
making it commercially available is a very important milestone for STRATA and its partner clinics. This new protocol will provide
faster patient outcomes, greater patient satisfaction, lower costs for payers and patients alike, and increased patient traffic to
our partner clinics. This dynamic combination of MMD’s proprietary technology and the OTD protocol is exclusively available to our
physician partners, differentiating their clinical delivery and adding to the technological superiority of the XTRAC platform as
compared with all other available treatment modalities. We look forward to the expansion of the commercial use of the MMD
diagnostic tip across our partner network of over 1,000 providers.”
About STRATA Skin Sciences, Inc. (www.strataskinsciences.com)
STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing
and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer
laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; and
the STRATAPEN® MicroSystem, marketed specifically for the intended use of micropigmentation. Nothing in this press
release is intended to indicate that the FDA has cleared the MMD device for marketing or that the sought after indications for use
will be allowed by the FDA.
The Company’s proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB light to treat
psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 35 million patients in the United States
alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatments to
vitiligo patients.
STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its
in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.
The XTRAC® business has used this proven DTC model to grow its domestic dermatology partner network to over 740
clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients an
introduction to physicians prescribing a reimbursable solution, using XTRAC®, within a 10-mile radius of their
house. The Company is a leader in dermatology in-clinic business generation for its partners.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995.
These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words
such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, including the Company’s
ability to generate the anticipated revenue stream, the Company’s ability to generate sufficient cash flow to fund the Company’s
ongoing operations and research and development activities beginning at any time in the future, the public’s reaction to the
Company’s new advertisements and marketing campaigns under development, and the Company’s ability to build a leading franchise in
dermatology and aesthetics, the Company’s ability to grow revenues and sustain that growth, and the Company’s ability to
secure FDA 510k clearance for the OTD device are based on the Company’s current expectations and are inherently subject to
significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to
financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the Company and the
medical device industry in general, as well as more specific risks and uncertainties set forth in the Company’s 10K filed with the
SEC on March 30, 2018.
Investor Contacts:
